Strides Announces Relaunch of Prescription Ranitidine Tablets

Strides Pharma is relaunching its prescription ranitidine 300 mg tablets in the U.S after testing for NDMA levels.

Strides said it completed “comprehensive testing” of ranitidine batches in the market and in stock and said the results were within the limits prescribed by the FDA.

Testing by the FDA also showed that the tablets were within the acceptable limits for NDMA of 96 nanograms per day or 0.32 ppm.